Ebola Success For Regeneron’s Triple Antibody Cocktail

 
• By Alexandra Shimmings

PALM study stopped early after two agents being tested proved better than ZMapp, the current standard of care, in the ongoing Ebola outbreak in the Democratic Republic of Congo. One is being developed by Regeneron.

Leaves
• Source: Shutterstock

More from Clinical Trials

More from R&D